Skip to main content
SpringerLink
Log in

Interleukin-2 therapy for human cancer

  • Biological Parameters In Lung Cancer
  • Published:
Lung Aims and scope Submit manuscript

Abstract

The concept of immunotherapy is evolving from nonspecific, haphazard stimulation of the immune apparatus to more specific and controlled manipulation of the immune system. IL-2 gives the opportunity to exert influence on the cellular immune system. Why LAK cells are able to lyse tumor cells and leave normal cells intact is not known. How LAK cells behave after reinfusion is not known; are they able to migrate to tumor sites? Can improvements be made in scheduling in order to decrease toxicity and to enhance efficacy? But first of all, the question arises whether the tremendous efforts required by adoptive transfer, in terms of toxicity, logistics, and money, are outweighed by the therapeutic results. For clinical practice inside the frontier of oncology, continuous infusion of IL-2 at an intermediate dose is a quite attractive option in finding a balance between efforts and results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coley WB (1893) Treatment of malignant tumors by repeated inoculations of eryspielas with a report of 10 cases. Med Rec 43:60

    Google Scholar 

  2. Shalaby MR, Pennica D, Palladino MA (1986) An overview of the history and biologic properties of tumor necrosis factor. Springer Semin Immunopathol 9:33–37

    Article  PubMed  CAS  Google Scholar 

  3. O’Garra A, Umland S, De France T, Christiansen J (1988) B-cell factors’ are pleiotropic. Immunology Today 9:45–54

    Article  PubMed  Google Scholar 

  4. Leonard WJ, Depper JM, Robb RJ, Waldmann TA, Greene WC (1983) Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci USA 80:6957–6961

    Article  PubMed  CAS  Google Scholar 

  5. Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ (1986) Novel Interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 234:859–863

    Article  PubMed  CAS  Google Scholar 

  6. Smith KA (1988) The bimolecular structure of the interleukin 2 receptor. Immunology Today 9:36–37

    Article  PubMed  CAS  Google Scholar 

  7. Stern JB, Smith KA (1986) Interleukin-2 induction of T-cell Gl progression and c-myb expression. Science 233:203–206

    Article  PubMed  CAS  Google Scholar 

  8. Kasahara T, Hooks JJ, Dougherty SF, Oppenheim JJ (1983) Interleukin-2 mediated immune interferon (IFN-gamma) production by human T-cells in T-cell subsets. J Immunol 130:1784–1789

    PubMed  CAS  Google Scholar 

  9. Kornfeld H, Berman JS, Beer DJ, Center DM (1985) Induction of human T lymphocyte motility by interleukin-2. J Immunol 134:3887–3890

    PubMed  CAS  Google Scholar 

  10. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin-2. J Immunol 134:157–166

    PubMed  CAS  Google Scholar 

  11. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lympholine-activated killer cell phenomenon. J Exp Med 155:1823–1841

    Article  PubMed  CAS  Google Scholar 

  12. Mulé JJ, Rosenberg SA (1989) Immunotherapy with lymphokine combinations. In: De Vita V, Hellman S, Rosenberg SA, eds. Important advances in oncology 1989. Philadelphia: JB Lippincott Company, pp 99–126

    Google Scholar 

  13. Rosenberg SA (1988) Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: De Vita V, Hellman S, Rosenberg SA, eds. Important advances in oncology 1988 Philadelphia: JB Lippincott Company, pp 213–257

    Google Scholar 

  14. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137:1735–1742

    PubMed  CAS  Google Scholar 

  15. West WH, Taner KW, Yannel JR, Marshall GD, Orr DW, Thurman GB, Oldham GK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905

    Article  PubMed  CAS  Google Scholar 

  16. Rosenberg SA, Lotze MT, Muul LM, Chang AE, et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897

    Article  PubMed  CAS  Google Scholar 

  17. Paciucci PA, Holland JF, Glidewell O, Odchimar R (1989) Recombinant IL-2 by continuous infusion and adoptive transfer of recombinant Interleukin-2-activated cells in patients with advanced cancer. J Clin Oncol 7:869–878

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Hospital Nÿmegen, Geert Grooteplein 10, NL-6525 GA, Nijmegen, The Netherlands

    Q. G. C. M. van Hoesel

Authors
  1. Q. G. C. M. van Hoesel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Hoesel, Q.G.C.M. Interleukin-2 therapy for human cancer. Lung 168 (Suppl 1), 1069–1074 (1990). https://doi.org/10.1007/BF02718245

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02718245

Key words

Search

Navigation